Lp-PLA2 levels are independant of statin treatment in dyslipidemic patients (original) (raw)

Comparative evaluation of the effect of statin drugs in Hyperlipidaemic patients

JAWAHAR FAROOK

2011

View PDFchevron_right

An overview of pleiotropic effect of statins in cardiovascular disease

Kumud Upadhyaya

Pharmacy & pharmacology international journal, 2018

View PDFchevron_right

Association between Lp-PLA 2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis

Natalie Khuseyinova

Atherosclerosis, 2005

View PDFchevron_right

Statins: effects beyond cholesterol lowering

Garry Shen

Nephrology Dialysis Transplantation, 2001

View PDFchevron_right

A correlation between LP-PLA2 and monocyte levels in atherosclerosis risk subjects

Kumboyono Kumboyono

Infekciâ i Immunitet, 2022

View PDFchevron_right

Lp-PLA2: A new target for statin therapy

Lynne Braun

Current atherosclerosis reports, 2010

View PDFchevron_right

Statin use, hyperlipidaemia, and the risk of breast cancer

Alec Walker

2002

View PDFchevron_right

Treatment of type III hyperlipoproteinemia with four different treatment regimens

Byron Hoogwerf

Atherosclerosis, 1984

View PDFchevron_right

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes

Valgerdur Steinthorsdottir

Journal of the American College of Cardiology, 2019

View PDFchevron_right

Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins

Juan Badimon

2000

View PDFchevron_right

Usefulness of Statin–Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease

Aurora Mendelsohn

The American Journal of Cardiology, 2009

View PDFchevron_right

Dyslipidemia: End Stage Renal Disease and Hemodialysis

E.Prabhakar Reddy

2009

View PDFchevron_right

Treating Hyperlipidemia for the Primary Prevention of Coronary Disease

Sylvie Perreault

Archives of internal medicine, 1998

View PDFchevron_right

Management of Dyslipidemia in the Metabolic Syndrome

Antonio Hernandez

American Journal of Cardiovascular Drugs, 2007

View PDFchevron_right

Atorvastatin treatment meets new European recommendations for the treatment of dyslipidemias

jana golob

Cardiologia Croatica, 2012

View PDFchevron_right

Assessment of a laboratory method for the evaluation of hyperlipoproteinemia

Alex Felice

1974

View PDFchevron_right

Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004

Angelo Marzo

Cancer Causes & Control, 2010

View PDFchevron_right

Dyslipidemia in Metabolic Syndrome: an Overview of Lipoprotein- Related Disorders

s Asha Devi

International Journal of Cardiology and Lipidology Research, 2017

View PDFchevron_right

Characterization of metabolic syndrome in PLIC cohort

Alberico Catapano

Atherosclerosis, 2017

View PDFchevron_right

Severity of coronary atherosclerosis related to lipoprotein concentration

Richard W Harper

BMJ, 1978

View PDFchevron_right

Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels

André Vis

Cancers, 2019

View PDFchevron_right

Secondary prevention of heart disease with statins: Authors' reply

Peter Davey

BMJ, 2005

View PDFchevron_right

Targeted study to evaluate the cardiovascular risk factor status among patients and efficacy of statins in attaining goal lipid levels in a regional hospital in Sultanate of Oman

Qasim Al Riyami

Saudi Pharmaceutical Journal, 2015

View PDFchevron_right

Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease

Angela Ren

Journal of the American College of Cardiology, 2014

View PDFchevron_right

Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle

Frank Church

BioEssays, 2007

View PDFchevron_right

Statin induced diabetes and its clinical implications

Ahmad Najmi

Journal of Pharmacology and Pharmacotherapeutics, 2014

View PDFchevron_right

The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort

Margaretha Persson

Atherosclerosis, 2007

View PDFchevron_right

Psychologic Disorders and Statin Use: A Propensity Score-Matched Analysis

Mary Jo Pugh

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013

View PDFchevron_right

Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention

Johanne Collin

British Journal of Clinical Pharmacology, 2005

View PDFchevron_right

Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients

Michael J Quon

International Journal of Cardiology, 2013

View PDFchevron_right

Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering

John Kjekshus

The American Journal of Cardiology, 2000

View PDFchevron_right

Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease

Raul Santos

Archives of Medical Research, 2014

View PDFchevron_right

Statins as potential therapeutic agents for healing disorders

Irena Pastar

… of Dermatology, 2010

View PDFchevron_right

ELEVATED LIPOPROTEIN (a) LEVELS SEEN IN PATIENTS WITH CORONARY ARTERY DISEASE

Prof. Iram Fayyaz

…, 2009

View PDFchevron_right

Dyslipidemia in women: etiology and management

binh phan

International Journal of Women's Health, 2014

View PDFchevron_right